Becker muscular dystrophy severity is linked to the structure of dystrophin

Human Molecular Genetics

Volumn 24, Issue 5, 2015, Pages 1267-1279

  Nicolas, Aurélie ^a,b   Raguènès Nicol, Céline ^a,b   Yaou, Rabah Ben ^c,d   Hir, Sarah Ameziane Le ^a,b   Chéron, Angélique ^a,b   Vié, Véronique ^a,e   Claustres, Mireille ^c,f,g   Leturcq, France ^c,h   Delalande, Olivier ^a,b   Hubert, Jean François ^a,b   Tuffery Giraud, Sylvie ^c,g   Giudice, Emmanuel ^a,b   Le Rumeur, Elisabeth ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

^g UNIV MONTPELLIER   (France)

^h Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; UREA;

ADOLESCENT; ADULT; ALPHA HELIX; ARTICLE; BECKER MUSCULAR DYSTROPHY; CELL HETEROGENEITY; CHILD; CIRCULAR DICHROISM; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EXON; GENE DELETION; GENETIC DIFFERENCE; HUMAN; HYBRID; HYDROPHOBICITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; MOTOR PERFORMANCE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; RETROSPECTIVE STUDY; WHEELCHAIR; WILD TYPE; AGED; ALLELE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARDIOMYOPATHY, DILATED; CLONING, MOLECULAR; DISEASE PROGRESSION; DYSTROPHIN; EXONS; GENE EXPRESSION REGULATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MIDDLE AGED; MODELS, MOLECULAR; MUSCULAR DYSTROPHY, DUCHENNE; PROTEIN STRUCTURE, SECONDARY; READING FRAMES; RETROSPECTIVE STUDIES; SEQUENCE DELETION; YOUNG ADULT;

EID: 84924455392     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu537     Document Type: Article

References (79)

1. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50, 509-517.
2. Koenig, M., Beggs, A., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Muller, C., Lindlof, M. and Kaariainen, H. (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet., 45, 498-506.
3. Bushby, K.M., Thambyayah, M. and Gardner-Medwin, D. (1991) Prevalence and incidence of Becker muscular dystrophy. Lancet, 337, 1022-1024.
4. Aartsma-Rus, A., Van Deutekom, J.C., Fokkema, I.F., Van Ommen, G.J. and Den Dunnen, J.T. (2006) Entries in the Leiden Duchenne muscular dystrophymutation database: an overviewofmutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve, 34, 135-144.
5. Mah, J.K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T. and Jette, N. (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord., 24, 482-491.
6. Beggs, A., Hoffman, E., Snyder, J., Arahata, K., Specht, L., Shapiro, F., Angelini, C., Sugita, H. and Kunkel, L. (1991) Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am. J. Hum. Genet., 49, 54-67.
7. Bushby, K.M. and Gardner-Medwin, D. (1993) The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J. Neurol., 240, 98-104.
8. Comi, G.P., Prelle, A., Bresolin, N., Moggio, M., Bardoni, A., Gallanti, A., Vita, G., Toscano, A., Ferro, M.T., Bordoni, A. et al. (1994) Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain, 117, 1-14.
9. Bladen, C.L., Rafferty, K., Straub, V., Monges, S., Moresco, A., Dawkins, H., Roy, A., Chamova, T., Guergueltcheva, V., Korngut, L. et al. (2013) The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum. Mutat., 34, 1449-1457.
10. Melacini, P., Fanin, M., Danieli, G.A., Fasoli, G., Villanova, C., Angelini, C., Vitiello, L., Miorelli, M., Buja, G.F., Mostacciuolo, M.L. et al. (1993) Cardiac involvement in Becker muscular dystrophy. J. Am. Coll. Cardiol., 22, 1927-1934.
11. Finsterer, J. and Stollberger, C. (2008) Cardiac involvement in Becker muscular dystrophy. Can. J. Cardiol., 24, 786-792.
12. Kaspar, R.W., Allen, H.D., Ray, W.C., Alvarez, C.E., Kissel, J.T., Pestronk, A., Weiss, R.B., Flanigan, K.M., Mendell, J.R. and Montanaro, F. (2009) Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ. Cardiovasc. Genet., 2, 544-551.
13. Romfh, A. and McNally, E.M. (2010) Cardiac assessment in Duchenne and becker muscular dystrophies. Curr. Heart Fail Rep., 7, 212-218.
14. Koenig, M., Monaco, A.P. and Kunkel, L.M. (1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell, 53, 219-226.
15. Le Rumeur, E.,Winder, S.J. and Hubert, J.F. (2010) Dystrophin: more than just the sum of its parts. Biochim. Biophys. Acta, 1804, 1713-1722.
16. Legrand, B., Giudice, E., Nicolas, A., Delalande, O. and LeRumeur, E. (2011) Computational study of the human dystrophin repeats: interaction properties and molecular dynamics. PLos ONE, 6, e23819.
17. Tuffery-Giraud, S., Beroud, C., Leturcq, F., Yaou, R.B., Hamroun, D., Michel-Calemard, L., Moizard, M.P., Bernard, R., Cossee, M., Boisseau, P. et al. (2009) Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum. Mutat., 30, 934-945.
18. Nicolas, A., Lucchetti-Miganeh, C., Ben Yaou, R., Kaplan, J.C., Chelly, J., Leturcq, F., Barloy-Hubler, F. and Le Rumeur, E. (2012) Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. Orphanet. J. Rare Dis., 7, 45.
19. Menhart, N. (2006) Hybrid spectrin type repeats produced by exon-skipping in dystrophin. Biochim. Biophys. Acta, 1764, 993-999.
20. Yokota, T., Duddy,W. and Patridge, T. (2007) Optimizing exon skipping therapies for DMD. Acta Myolog., 26, 179-184.
21. Winder, S.J., Gibson, T.J. and Kendrick-Jones, J. (1995) Dystrophin and utrophin: the missing links! FEBS Lett., 369, 27-33.
22. Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst., 26, 283-291.
23. Muthu, M., Richardson, K.A. and Sutherland-Smith, A.J. (2012) The crystal structures of dystrophin and utrophin spectrin repeats: implications for domain boundaries. PLoS ONE, 7, e40066.
24. Legardinier, S., Raguénès-Nicol, C., Tascon, C., Rocher, C., Hardy, S., Hubert, J.F. and Le Rumeur, E. (2009) Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. J. Mol. Biol., 389, 546-558.
25. Legardinier, S., Hubert, J.-F., Le Bihan, O., Tascon, C., Rocher, C., Raguénès-Nicol, C., Bondon, A., Hardy, S. and Le Rumeur, E. (2008) Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties. Biochim. Biophys. Acta, 1784, 672-682.
26. Magri, F., Govoni, A., D'Angelo, M.G., Del Bo, R., Ghezzi, S., Sandra, G., Turconi, A.C., Sciacco, M., Ciscato, P., Bordoni, A. et al. (2011) Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J. Neurol., 258, 1610-1623.
27. Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomeza, V., Armaroli, A., Guglieri, M., Straathof, C.S., Verschuuren, J.J. et al. (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain, 134, 3544-3556.
28. Jarmin, S., Kymalainen, H., Popplewell, L. and Dickson, G. (2014) New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin. Biol. Ther., 14, 209-230.
29. Wilton, S.D., Fletcher, S. and Flanigan, K.M. (2014) Dystrophin as a therapeutic biomarker: are we ignoring data from the past? Neuromuscul. Disord., 24, 463-466.
30. Morandi, L., Mora, M., Confalonieri, V., Barresi, R., Di Blasi, C., Brugnoni, R., Bernasconi, P., Mantegazza, R., Dworzak, F., Antozzi, C. et al. (1995) Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. J. Neurol. Sci., 132, 146-155.
31. van den Bergen, J.C., Schade van Westrum, S.M., Dekker, L., van der Kooi, A.J., de Visser, M., Wokke, B.H., Straathof, C.S., Hulsker, M.A., Aartsma-Rus, A., Verschuuren, J.J. et al. (2013) Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. J. Neurol. Neurosurg. Psychiatry, 85, 92-98.
32. Bushby, K.M., Gardner-Medwin, D., Nicholson, L.V., Johnson, M.A., Haggerty, I.D., Cleghorn, N.J., Harris, J.B. and Bhattacharya, S.S. (1993) The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J. Neurol., 240, 105-112.
33. van den Bergen, J.C.,Wokke, B.H., Janson, A.A., van Duinen, S.G., Hulsker,M.A.,Ginjaar,H.B.,vanDeutekom, J.C.,Aartsma-Rus,A., Kan, H.E. and Verschuuren, J.J. (2014) Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry, 85, 747-753.
34. Aartsma-Rus, A. (2014) Dystrophin analysis in clinical trials. J. Neuromuscul. Dis., 1, 41-53.
35. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C. et al. (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord., 17, 913-918.
36. Carsana, A., Frisso, G., Tremolaterra, M.R., Lanzillo, R., Vitale, D.F., Santoro, L. and Salvatore, F. (2005) Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. Ann. Hum. Genet., 69, 253-259.
37. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. et al. (2002)Modular flexibilityof dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8, 253-261.
38. England, S., Nicholson, L., Johnson, M., Forrest, S., Love, D., Zubrzycka-Gaarn, E., Bulman, D., Harris, J. and Davies, K. (1990) Very mild muscular dystrophy associated with the deletion of 46% of the dystrophin. Nature, 343, 180-182.
39. Ferrer, A., Foster, H., Wells, K.E., Dickson, G. and Wells, D.J. (2004) Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene Ther., 11, 884-893.
40. Draviam, R.A.,Wang, B., Li, J., Xiao, X. andWatkins, S.C. (2006) Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells. J. Muscle Res. Cell Motil., 27, 53-67.
41. Wang, Z., Kuhr, C.S., Allen, J.M., Blankinship, M., Gregorevic, P., Chamberlain, J.S., Tapscott, S.J. and Storb, R. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther., 15, 1160-1166.
42. Banks, G.B., Combs, A.C., Chamberlain, J.R. and Chamberlain, J.S. (2008) Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum. Mol. Genet., 17, 3975-3986.
43. Foster, H., Popplewell, L. and Dickson, G. (2012) Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum. Gene Ther., 23, 676-687.
44. Henderson, D.M., Belanto, J.J., Li, B., Heun-Johnson, H. and Ervasti, J.M. (2011) Internal deletion compromises the stability of dystrophin. Hum. Mol. Genet., 20, 2955-2963.
45. Petrof, B.J., Shrager, J.B., Stedmann, H.H., Kelly, A.M. and Sweeney, H.L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA, 90, 3710-3714.
46. Deconinck, N. and Dan, B. (2007) Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol., 36, 1-7.
47. Nicolas, A., Delalande, O., Hubert, J.F. and Le Rumeur, E. (2014) The spectrin family of proteins: a unique coiled-coil fold for various molecular surface properties. J. Struct. Biol., 186, 392-401.
48. Helderman-van den Enden, A.T., Straathof, C.S., Aartsma-Rus, A., den Dunnen, J.T., Verbist, B.M., Bakker, E., Verschuuren, J.J. and Ginjaar, H.B. (2010) Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul. Disord., 20, 251-254.
49. Amann, K.J., Renley, B.A. and Ervasti, J.M. (1998) A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. Chem., 273, 28419-28423.
50. Ervasti, J.M. (2006) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta, 1772, 108-117.
51. Schwartz, M., Duno, M., Palle, A.L., Krag, T. and Vissing, J. (2007) Deletion of exon 16 of the dystrophin gene is not associated with disease. Hum. Mutat., 28, 205.
52. Witting, N., Duno, M. and Vissing, J. (2011) Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. Acta Myolog., 30, 182-184.
53. Lai, Y., Thomas, G.D., Yue, Y., Yang, H.T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J.S., Terjung, R.L. et al. (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest., 119, 624-635.
54. Giudice, E., Molza, A.-E., Laurin, Y., Nicolas, A., Le Rumeur, E. and Delalande, O. (2013) Molecular clues to the dystrophin- nNOS interaction: a theoretical approach. Biochemistry, 52, 7777-7784.
55. Beroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V.,Monnier, N., Moizard, M.P., Voelckel, M.A., Calemard, L.M., Boisseau, P. et al. (2007)Multiexon skipping leading to an artificialDMD protein lacking amino acids fromexons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat., 28, 196-202.
56. Gentil, C., Leturcq, F., Ben Yaou, R., Kaplan, J.C., Laforet, P., Penisson-Besnier, I., Espil-Taris, C., Voit, T., Garcia, L. and Pietri-Rouxel, F. (2012) Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation. Hum. Mol. Genet., 21, 3449-3460.
57. Dwianingsih, E.K., Malueka, R.G., Nishida, A., Itoh, K., Lee, T., Yagi, M., Iijima, K., Takeshima, Y. and Matsuo, M. (2014) A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. J. Hum. Genet., 59, 423-429.
58. Flanigan, K.M., Dunn, D.M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E., Howard, M.T., Sampson, J.B., Mendell, J.R., Wall, C., King, W.M. et al. (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum. Mutat., 30, 1657-1666.
59. Cacchiarelli, D., Incitti, T., Martone, J., Cesana, M., Cazzella, V., Santini, T., Sthandier, O. and Bozzoni, I. (2011) miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep., 12, 136-141.
60. Kerst, B., Mennerich, D., Schuelke, M., Stoltenburg-Didinger, G., von Moers, A., Gossrau, R., van Landeghem, F.K., Speer, A., Braun, T. and Hubner, C. (2000) Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy. Neuromuscul. Disord., 10, 572-577.
61. Davis, D.B., Delmonte, A.J., Ly, C.T. and McNally, E.M. (2000) Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum. Mol. Genet., 9, 217-226.
62. Pegoraro, E., Hoffman, E.P., Piva, L., Gavassini, B.F., Cagnin, S., Ermani, M., Bello, L., Soraru, G., Pacchioni, B., Bonifati, M.D. et al. (2011) SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology, 76, 219-226.
63. Bello, L., Piva, L., Barp, A., Taglia, A., Picillo, E., Vasco, G., Pane, M., Previtali, S.C., Torrente, Y., Gazzerro, E. et al. (2012) Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 79, 159-162.
64. Aartsma-Rus, A. (2010) Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol., 7, 453-461.
65. Hoffman, E.P. and Connor, E.M. (2013) Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov. Med., 16, 233-239.
66. Fairclough, R.J.,Wood, M.J. and Davies, K.E. (2013) Therapy for Duchenne muscular dystrophy: renewed optimism fromgenetic approaches. Nat. Rev. Genet., 14, 373-378.
67. Ameziane-Le Hir, S., Raguénès-Nicol, C., Paboeuf, G., Nicolas, A., Chéron, A., Le Rumeur, E. and Vié, V. (2014) Cholesterol favors higher level of insertion and organization of spectrinlike repeat 16-21 of human dystrophin in membrane. Biochim. Biophys. Acta, 1838, 1266-1273.
68. Phillips, J.C., Braun, R.,Wang,W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D., Kale, L. and Schulten, K. (2005) Scalable molecular dynamics with NAMD. J. Comput. Chem., 26, 1781-1802.
69. Felsenstein, J. (1987) Estimation of hominoid phylogeny from a DNA hybridization data set. J. Mol. Evol., 26, 123-131.
70. Baker, N.A., Sept, D., Joseph, S., Holst, M.J. and McCammon, J. A. (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA, 98, 10037-10041.
71. Mackerell, A.D., Bashford, D., Bellott, M., Dunbrack, R.L. Jr, Evanseck, J., Field, M.J., Fischer, S., Gao, J., Guo, H., Ha, S. et al. (1998) All atom empirical potential for molecular modeling and dynamics studies of protein. J. Phys. Chem. B, 102, 3586-3615.
72. Foloppe, N. and Mackerell, A.D. Jr. (2000) Parameter optimization based on small molecule and condensed phase macromolecular target. J. Comput. Chem., 21, 86-104.
73. MacKerell, A.D. Jr and Banavali, N. (2000) Application to molecular dynamics simulations of DNA and RNA in solution. J. Comput. Chem., 21, 105-120.
74. Mackerell, A.D. Jr, Feig, M. and Brooks, C.L. 3rd (2004) Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem., 25, 1400-1415.
75. Efremov, R.G., Chugunov, A.O., Pyrkov, T.V., Priestle, J.P., Arseniev, A.S. and Jacoby, E. (2007) Molecular lipophilicity in protein modeling and drug design. Curr. Med. Chem., 14, 393-415.
76. Pyrkov, T.V., Chugunov, A.O., Krylov, N.A., Nolde, D.E. and Efremov, R.G. (2009) PLATINUM: a web tool for analysis of hydrophobic/hydrophilic organization of biomolecular complexes. Bioinformatics, 25, 1201-1202.
77. Kahana, E. and Gratzer, W.B. (1995) Minimum folding unit of dystrophin rod domain. Biochemistry, 34, 8110-8114.
78. Legardinier, S., Legrand, B., Raguénès-Nicol, C., Bondon, A., Hardy, S., Tascon, C., Le Rumeur, E. and Hubert, J.F. (2009) A two amino-acid mutation encountered in Duchenne muscular dystrophy decreases stability of the R23 spectrin-like repeat of dystrophin. J. Biol. Chem., 284, 8822-8832.
79. Anderson, L.V. and Davison, K. (1999) MultiplexWestern blotting system for the analysis of muscular dystrophy proteins. Am. J. Pathol., 154, 1017-1022.